Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma - updated results after 18-year follow-up

Leukemia. 2024 May;38(5):1169-1171. doi: 10.1038/s41375-024-02192-z. Epub 2024 Feb 28.

Affiliations

¹ Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
² Division of Hematology, Department of Medicine, Mayo Clinic, Jacksonville, FL, USA.
³ Division of Hematology/Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA.
⁴ Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA. rajkumar.vincent@mayo.edu.

PMID: 38418610
DOI: 10.1038/s41375-024-02192-z

No abstract available

Publication types

Clinical Trial, Phase III
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Letter

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Female
Follow-Up Studies
Humans
Male
Middle Aged
Multiple Myeloma* / drug therapy
Multiple Myeloma* / therapy
Prognosis
Survival Rate